Assessment of Cardiovascular Toxicities in Immuno-oncology Trials

This public workshop, hosted by the FDA, is a forum for discussion of cardiovascular toxicities in immuno-oncology clinical trials. The focus of the workshop is to identify best practices to assess cardiovascular and metabolic toxicities in patients receiving cancer immunotherapies. The workshop will be held at the FDA White Oak Campus from 8:30am to 5pm, and there will be a webcast available to those who register.

Location: FDA White Oak Campus
10903 New Hampshire Avenue
Building 31, Room 1503 – Great Room A
Silver Spring, MD 20993

Webcast Information:
FDA will provide a free-of-charge, live webcast of the December 1, 2017 workshop, Assessment of Cardiovascular Toxicities in Immunotherapy Trials. Due to room size, registration is limited to 110 people. Further information regarding the webcast, including the web link for the webcast, will be made available closer to the workshop date. FDA plans to post archived webcasts after the meeting, however, in cases where transmission was not successful, archived webcasts will not be available.

Co-Chairs: Laleh Amiri-Kordestani, MD and Javid Moslehi, MD

Registration to Attend the Workshop: 
In-person Registration is limited to first 110 people; however, webcast will be available to all who register. To register click on the link: Cardio Oncology Workshop – Friday, December 1, 2017